{"classes":[{"categories":[{"measurements":[{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG000","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG001","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG002","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG003","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG004","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG005","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG006","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG007","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG008","value":"NA"},{"comment":"The very small number of patients in each cohort and the very low levels of positivity resulted in a non-reportable value","groupId":"OG009","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"6"},{"groupId":"OG008","value":"4"},{"groupId":"OG009","value":"4"}],"units":"Participants"}],"description":"Samples were collected to determine the presence of an immunologic reaction to MM-121 (i.e. human anti-human antibodies).","groups":[{"description":"MM-121: 12 mg/kg IV weekly in 4-week cycles Cetuximab: 400 mg/m2 IV one-time loading dose followed by 200 mg/m2 IV weekly maintenance doses","id":"OG000","title":"Part 1: Cohort 1"},{"description":"MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW","id":"OG001","title":"Part 1: Cohort 2a"},{"description":"MM-121: 12 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW","id":"OG002","title":"Part 1: Cohort 2b"},{"description":"MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW","id":"OG003","title":"Part 1: Cohort 3a"},{"description":"MM-121: 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW","id":"OG004","title":"Part 1: Cohort 3b"},{"description":"MM-121: 40 mg/kg one time loading dose followed by 20 mg/kg IV QW Cetuximab: 400 mg/m2 one-time loading dose followed by 250 mg/m2 maintenance IV QW","id":"OG005","title":"Part 1: Cohort 4"},{"description":"MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW Cetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW","id":"OG006","title":"Part 1: Expansion Cohort"},{"description":"MM-121: 20 mg/kg IV QW\n\nCetuximab: 400 mg/m2 loading dose followed by 200 mg/m2 maintenance IV QW\n\nIrinotecan: 180 mg/m2 IV Q2W","id":"OG007","title":"Part 2: Cohort 1"},{"description":"MM-121: 40 mg/kg loading dose followed by 20 mg/kg IV QW\n\nCetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW\n\nIrinotecan: 180 mg/m2 IV Q2W","id":"OG008","title":"Part 2: Cohort 2"},{"description":"MM-121: 20 mg/kg IV QW\n\nCetuximab: 400 mg/m2 loading dose followed by 250 mg/m2 maintenance IV QW\n\nIrinotecan: 180 mg/m2 IV Q2W","id":"OG009","title":"Part 2: Expansion Cohort"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Samples were collected for all patients pre-dose on all cycles for duration of treatment, the longest of which was 48.1 weeks, and a collection was made post-infusion in any case of infusion reaction","title":"Immunogenicity","type":"SECONDARY"}